[A22-05] Amivantamab (NSCLC) - Benefit assessment according to §35a Social Code Book V
Last updated 19.04.2022
Project no.:
A22-05
Commission:
Commission awarded on 17.01.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with locally advanced or metastatic NSCLC with activating EGFR exon 20 insertion mutations after failure of platinum-based chemotherapy
Result of dossier assessment:
- Patients for whom further chemotherapy is indicated: added benefit not proven.
- Patients for whom no further therapy is indicated: added benefit not proven.
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.